TAL1 (Ab-122) Antibody

What is the specificity and reactivity of TAL1 (Ab-122) Antibody?

TAL1 (Ab-122) Antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of total TAL1 protein. It was developed using a synthesized non-phosphopeptide derived from human TAL1 around the phosphorylation site of serine 122 (Q-L-S(p)-P-P) as the immunogen . The antibody shows reactivity with both human and mouse samples, making it versatile for comparative studies across these species . This antibody recognizes TAL1 protein, also known as T-cell acute lymphocytic leukemia protein 1, SCL, or TCL5, which has a molecular weight of approximately 45 kDa as determined by SDS-PAGE .

The specificity of this antibody makes it particularly valuable for studying TAL1's role in hematopoietic differentiation and malignancies. The antibody was affinity-purified from rabbit antiserum using epitope-specific immunogen through affinity chromatography, which enhances its specificity for the target protein .

What are the recommended applications and dilutions for TAL1 (Ab-122) Antibody?

The TAL1 (Ab-122) Antibody has been validated for Western Blot (WB) applications with a recommended dilution range of 1:500-1:3000 . It is also suitable for ELISA applications . For optimal results in Western Blot applications, researchers should:

• Prepare protein samples in standard SDS-PAGE loading buffer

• Use a suitable transfer membrane (PVDF or nitrocellulose)

• Block with 5% non-fat milk or BSA in TBST

• Incubate with primary antibody at the recommended dilution (1:500-1:3000)

• Wash thoroughly with TBST

• Use an appropriate HRP-conjugated secondary antibody

• Develop using ECL or other chemiluminescent detection systems

The antibody is supplied at a concentration of 1.0 mg/ml in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150 mM NaCl, 0.02% sodium azide, and 50% glycerol . This formulation contributes to its stability during storage and use.

How should TAL1 (Ab-122) Antibody be stored and handled for optimal performance?

For optimal performance and longevity of the TAL1 (Ab-122) Antibody, proper storage and handling practices are essential. The antibody should be stored at -20°C immediately upon receipt . Some sources also suggest that storage at -80°C is acceptable . It's important to avoid repeated freeze-thaw cycles as this can lead to antibody degradation and loss of performance .

When working with the antibody, aliquoting into single-use volumes is recommended to minimize freeze-thaw cycles. The antibody is supplied in liquid form in a buffer containing 50% glycerol, which prevents freezing at -20°C and allows for direct pipetting without thawing completely .

For long-term storage integrity, maintain a consistent cold chain and handle the antibody using sterile techniques to prevent contamination. Prior to use, gently mix the antibody solution by inverting the tube rather than vortexing, which can lead to protein denaturation.

How can TAL1 (Ab-122) Antibody be optimized for chromatin immunoprecipitation (ChIP) experiments to study TAL1 binding sites?

While TAL1 (Ab-122) Antibody is primarily validated for Western Blot applications, its specificity makes it a potential candidate for chromatin immunoprecipitation (ChIP) experiments with proper optimization. Based on TAL1 ChIP-seq studies, successful implementation requires carefully controlled conditions:

• Cross-linking Optimization: TAL1 as a transcription factor typically requires formaldehyde fixation (1% for 10 minutes at room temperature) to preserve protein-DNA interactions .

• Sonication Parameters: Fragment chromatin to 200-500 bp for optimal TAL1 binding site resolution . This range has been shown to effectively capture both promoter and enhancer elements bound by TAL1.

• Antibody Concentration: Start with 5-10 μg per ChIP reaction and optimize based on signal-to-noise ratio. For TAL1 (Ab-122) specifically, preliminary titration experiments are recommended due to its original optimization for Western Blot applications.

• Controls: Include IgG negative controls and positive controls targeting known TAL1 binding regions like those in erythroid genes (e.g., Epb4.2, Gypa) .

• Sequential ChIP Considerations: For studying TAL1 complexes with other factors, sequential ChIP protocols may be implemented, with TAL1 (Ab-122) Antibody used in either the first or second immunoprecipitation step .

Research has shown that TAL1 binding sites often contain E-box motifs (CANNTG), and successful ChIP experiments with TAL1 antibodies have identified both direct DNA-binding and indirect binding mechanisms through protein-protein interactions .

What methodological approaches should be used to distinguish between direct and indirect TAL1 DNA binding when using TAL1 (Ab-122) Antibody?

TAL1, as a bHLH transcription factor, can bind DNA both directly through E-box motifs and indirectly through protein-protein interactions. When using TAL1 (Ab-122) Antibody in ChIP or related experiments, several methodological approaches can help distinguish between these binding modes:

• Comparative Analysis with TAL1 DNA-Binding Mutants: Studies using Tal1RER/RER mutants (which lack direct DNA-binding capability) alongside wild-type samples can help categorize binding sites . Sites absent in the mutant but present in wild-type represent direct DNA binding, while sites retained in both indicate indirect binding.

• Motif Analysis: Bioinformatic analysis of TAL1-bound regions can identify enriched DNA motifs. Direct binding sites typically contain E-box motifs (CANNTG), while indirect binding sites may lack these motifs but contain binding sequences for TAL1 partners .

• Sequential ChIP (Re-ChIP): This technique can determine if TAL1 is part of specific transcriptional complexes at particular genomic loci. For example, TAL1 has been shown to interact with the UTX complex, and sequential ChIP can verify co-occupancy .

• Integration with Expression Data: Combining ChIP-seq with gene expression analysis from TAL1 wild-type versus knockdown or mutant cells helps identify functionally relevant binding events. Research has shown that only a subset of TAL1-bound genes (approximately 83 out of 2,195) show altered expression upon loss of direct TAL1 DNA binding .

• Partner Protein Analysis: Immunoprecipitation followed by mass spectrometry has identified TAL1-interacting proteins like components of the UTX complex . Analyzing these interactions in conjunction with chromatin binding can help understand the mechanism of binding at specific loci.

This methodological framework has revealed that TAL1 regulates genes involved in multiple erythroid processes, with both direct and indirect binding contributing to its function .

How can TAL1 (Ab-122) Antibody be used to investigate the role of TAL1 in T-cell acute lymphoblastic leukemia (T-ALL)?

TAL1 (Ab-122) Antibody can be instrumental in investigating TAL1's critical role in T-ALL through multiple experimental approaches:

• Protein Expression Analysis: Western blotting using TAL1 (Ab-122) Antibody can quantify TAL1 protein levels across T-ALL cell lines and patient samples to establish correlation with disease progression and treatment response .

• Chromatin Landscape Analysis: When optimized for ChIP applications, this antibody can help identify TAL1 binding sites in leukemic cells, particularly at oncogenic loci. TAL1 has been shown to drive leukemogenesis through transcriptional regulatory networks .

• Partner Protein Interactions: Co-immunoprecipitation using TAL1 (Ab-122) Antibody can identify TAL1-interacting proteins in T-ALL. Studies have shown that TAL1 interacts with the UTX complex, and this interaction may be critical for its oncogenic function .

• Allelic Expression Analysis: When combined with RNA-seq and genomic sequencing, TAL1 protein detection can help understand allele-specific expression patterns. Research has shown that TAL1-positive T-ALL samples often display monoallelic TAL1 expression, indicating cis-deregulation mechanisms .

• Therapeutic Target Validation: The antibody can help evaluate the efficacy of potential therapeutic strategies targeting TAL1 or its downstream pathways. Research has shown that TAL1 knockdown induces apoptosis in T-ALL cells, highlighting its potential as a therapeutic target .

A methodological workflow might involve:

• Initial Western blot screening of patient samples to identify TAL1-positive cases

• ChIP-seq to map TAL1 binding sites and identify target genes

• RNA-seq to correlate binding with gene expression changes

• Functional validation of key targets through knockdown/overexpression studies

• Evaluation of potential therapeutic compounds that disrupt TAL1 function or interactions

This comprehensive approach has revealed that TAL1 activation in T-ALL often involves cis-regulatory mechanisms and results in monoallelic expression .

What are common technical issues when using TAL1 (Ab-122) Antibody in Western blotting and how can they be resolved?

When working with TAL1 (Ab-122) Antibody in Western blotting, researchers may encounter several technical challenges. Here are common issues and their methodological solutions:

• High Background Signal:

  • Problem: Non-specific binding resulting in high background.

  • Solution: Optimize blocking conditions by testing different blocking agents (5% non-fat milk, 3-5% BSA) and increasing blocking time to 2 hours at room temperature. Additionally, increase wash duration and frequency (5-6 washes, 10 minutes each) with 0.1% Tween-20 in TBS .

• Weak or No Signal:

  • Problem: Insufficient protein, degraded antibody, or suboptimal detection.

  • Solution: Increase protein loading (50-80 μg per lane), use freshly prepared samples, reduce dilution of primary antibody (try 1:500 instead of 1:3000), and extend primary antibody incubation to overnight at 4°C . TAL1 has a molecular weight of approximately 45 kDa, so ensure appropriate gel percentage and transfer conditions.

• Multiple Bands:

  • Problem: Detection of non-specific proteins or TAL1 isoforms/degradation products.

  • Solution: Increase antibody specificity by pre-absorbing with blocking peptide when available, use freshly prepared lysates with protease inhibitors, and optimize SDS-PAGE conditions. TAL1 may show multiple bands due to post-translational modifications or alternative splicing.

• Inconsistent Results Across Cell Types:

  • Problem: Variable TAL1 expression or accessibility.

  • Solution: Optimize lysis conditions for different cell types (RIPA vs. NP-40 buffer), adjust protein loading based on expected TAL1 expression levels, and include positive control lysates from cells known to express TAL1 (e.g., erythroid precursors or certain T-ALL cell lines) .

• Protein Transfer Issues:

  • Problem: Incomplete transfer of higher molecular weight proteins.

  • Solution: For TAL1 (45 kDa), use standard semi-dry or wet transfer protocols, but extend transfer time to 90 minutes or reduce methanol concentration in transfer buffer to improve efficiency.

Following these methodological adjustments can significantly improve Western blot results with TAL1 (Ab-122) Antibody, ensuring reliable and reproducible detection of TAL1 protein.

How can TAL1 (Ab-122) Antibody be used in co-immunoprecipitation experiments to identify TAL1 interaction partners?

TAL1 (Ab-122) Antibody can be effectively adapted for co-immunoprecipitation (co-IP) experiments to identify and characterize TAL1 protein-protein interactions following this optimized protocol:

• Cell Lysis Optimization:

  • Use gentle lysis buffers containing 0.5-1% NP-40 or 0.5% Triton X-100 with low salt concentration (150 mM NaCl) to preserve protein-protein interactions.

  • Include protease and phosphatase inhibitors to prevent degradation and maintain phosphorylation status, particularly important for the serine 122 region recognized by this antibody .

• Pre-clearing Step:

  • Pre-clear lysates with Protein A/G beads to reduce non-specific binding.

  • Reserve 5-10% of pre-cleared lysate as input control for downstream analysis.

• Antibody Binding:

  • Incubate 2-5 μg of TAL1 (Ab-122) Antibody with pre-cleared lysate overnight at 4°C with gentle rotation.

  • For negative control, use matched concentration of rabbit IgG.

• Immunoprecipitation:

  • Add pre-washed Protein A or Protein A/G beads and incubate for 2-4 hours at 4°C.

  • Perform extensive washing (minimum 5 washes) with decreasing salt concentrations to maintain specific interactions while removing non-specific binding.

• Complex Elution and Analysis:

  • Elute complexes with SDS loading buffer at 70°C (instead of boiling) to reduce IgG contamination.

  • Analyze by SDS-PAGE followed by Western blotting for suspected interaction partners or mass spectrometry for unbiased discovery.

This approach has successfully identified TAL1 interactions with components of the UTX complex in T-ALL nuclear extracts . When performing reverse co-IP, reciprocal immunoprecipitations using antibodies against endogenous TAL1 and UTX proteins have confirmed their interaction .

For validation of novel interactions, in vitro binding experiments with recombinant proteins can determine if interactions are direct, as demonstrated for the TAL1-UTX interaction mediated by the bHLH domain of TAL1 .

What methodology should be used to analyze TAL1 genomic binding patterns when using TAL1 (Ab-122) Antibody in ChIP-seq experiments?

When adapting TAL1 (Ab-122) Antibody for ChIP-seq experiments to analyze TAL1 genomic binding patterns, researchers should implement this comprehensive analytical framework:

• Sample Preparation and Sequencing:

  • For optimal results, use Ter119- erythroid cell populations or relevant leukemic cell lines with confirmed TAL1 expression .

  • Include appropriate controls: Input DNA, IgG ChIP, and when possible, TAL1 DNA-binding mutants (e.g., Tal1RER/RER) for distinguishing direct from indirect binding .

  • Target 20-30 million uniquely mapped reads per sample for comprehensive coverage of TAL1 binding sites.

• Data Analysis Pipeline:

  • Quality Control: Filter low-quality reads (Q<30) and remove PCR duplicates.

  • Mapping: Align to appropriate reference genome using Bowtie2 or BWA with parameters optimized for ChIP-seq.

  • Peak Calling: Use MACS2 with q-value cutoff of 0.01-0.05 and appropriate peak width parameters for transcription factors (typically 150-300 bp).

  • Differential Binding Analysis: Compare wild-type vs. mutant binding profiles to categorize direct and indirect binding events .

• Functional Annotation:

  • Genomic Distribution: Analyze distribution of peaks relative to genomic features (promoters, enhancers, introns, etc.).

  • Motif Analysis: Perform de novo and known motif enrichment analysis using MEME suite or similar tools to identify direct binding sites (E-box motifs) versus co-factor binding sites.

  • Integration with Epigenomic Data: Correlate TAL1 binding with histone modifications (e.g., H3K4me3, H3K27ac) to identify active regulatory elements .

• Gene Expression Correlation:

  • Integrate ChIP-seq with RNA-seq data from wild-type and TAL1-deficient cells to identify functionally relevant binding events.

  • Previous studies identified 83 genes as direct TAL1 targets from an intersection of ChIP-seq and differential expression data .

• Functional Classification and Network Analysis:

  • Perform pathway enrichment analysis on TAL1 target genes using tools like Ingenuity Pathway Analysis.

  • TAL1 targets are typically enriched in hematopoietic development, erythroid differentiation, and related cellular processes .

This analytical approach has revealed that TAL1 binds to diverse genomic targets involved in multiple aspects of erythroid development and function, including heme pathway enzymes, membrane proteins, and oxidative stress response genes .

How can TAL1 (Ab-122) Antibody contribute to understanding the dual role of TAL1 in normal hematopoiesis versus leukemogenesis?

TAL1 (Ab-122) Antibody provides a valuable tool for dissecting the seemingly contradictory roles of TAL1 in normal development versus malignant transformation. A comprehensive research approach using this antibody would include:

• Comparative Binding Pattern Analysis:

  • Perform ChIP-seq using TAL1 (Ab-122) Antibody in normal hematopoietic progenitors versus leukemic cells to identify differential binding patterns .

  • Compare genomic locations, binding strengths, and co-factors across cellular contexts.

  • Research has shown that TAL1 regulates distinct gene sets in normal erythroid development compared to T-ALL, despite using similar DNA binding mechanisms .

• Protein Complex Composition Profiling:

  • Use TAL1 (Ab-122) Antibody for immunoprecipitation followed by mass spectrometry in normal versus malignant cells.

  • Identify context-specific interaction partners that may explain differential functions.

  • The interaction between TAL1 and the UTX complex appears particularly relevant in the leukemic context .

• Phosphorylation Status Analysis:

  • Since TAL1 (Ab-122) Antibody targets a region around the serine 122 phosphorylation site, it can be used alongside phospho-specific antibodies to determine how phosphorylation affects TAL1 function in different contexts .

  • Compare phosphorylation patterns between normal and leukemic cells using phosphatase treatments and phospho-specific Western blotting.

• Allelic Expression Studies:

  • Combine TAL1 protein detection with allele-specific expression analysis to understand regulatory mechanisms.

  • Research has shown that TAL1-positive T-ALL samples often display monoallelic TAL1 expression, indicating cis-deregulation .

• Functional Validation Through Genetic Manipulation:

  • Use CRISPR/Cas9 to modify TAL1 in normal and malignant contexts, then detect resulting protein changes with TAL1 (Ab-122) Antibody.

  • Create domain-specific mutations to dissect which TAL1 functions are essential in each context.

This multi-faceted approach can help elucidate how the same transcription factor promotes normal differentiation in one context while driving malignant transformation in another.

What are the methodological considerations for using TAL1 (Ab-122) Antibody in high-throughput screening approaches to identify novel therapeutic targets in TAL1-dependent leukemias?

Using TAL1 (Ab-122) Antibody in high-throughput screening approaches to identify novel therapeutic targets requires careful methodological design:

• Assay Development for Primary Screening:

  • Antibody-Based Reporter Systems: Develop cellular assays where TAL1 protein levels or localization (detected by TAL1 (Ab-122) Antibody) serve as readouts for compound screening.

  • Target Engagement Assays: Implement cellular thermal shift assays (CETSA) using TAL1 (Ab-122) Antibody to detect compounds that directly bind and stabilize/destabilize TAL1.

  • Proximity-Based Assays: Develop FRET or BRET systems incorporating TAL1 (Ab-122) Antibody derivatives to screen for compounds disrupting specific protein-protein interactions, such as TAL1-UTX .

• Secondary Validation Methodologies:

  • Dose-Response Assessment: Validate hits using Western blot with TAL1 (Ab-122) Antibody across concentration ranges.

  • Target Specificity Confirmation: Employ ChIP-qPCR at known TAL1 binding sites to confirm that compounds affect genomic occupancy.

  • Functional Consequences: Correlate changes in TAL1 binding/expression with functional outcomes using cell viability, apoptosis, and differentiation assays.

• Advanced Target Validation Strategies:

  • Combinatorial Approaches: Test compound effects in combination with epigenetic modifiers, particularly those affecting the UTX complex .

  • Genetic Validation: Compare compound effects in isogenic cell lines with wild-type TAL1 versus DNA-binding mutants (TAL1RER) to determine mechanism specificity .

  • Patient-Derived Xenograft Models: Use TAL1 (Ab-122) Antibody for immunohistochemistry/Western blot to monitor TAL1 expression in PDX models treated with candidate compounds.

• Technical Optimizations for High-Throughput Applications:

  • Miniaturization: Optimize antibody concentration and detection methods for 384/1536-well formats.

  • Automation Compatibility: Ensure consistent performance with automated liquid handling and washing steps.

  • Data Normalization: Develop robust normalization strategies accounting for well-to-well variations in cell number and antibody binding.

• Translational Considerations:

  • Biomarker Development: Use TAL1 (Ab-122) Antibody to develop immunoassays for patient stratification based on TAL1 expression or activation status.

  • Resistance Mechanisms: Monitor changes in TAL1 expression, localization, or post-translational modifications during development of resistance.

This comprehensive approach leverages the specificity of TAL1 (Ab-122) Antibody to identify compounds that could selectively target TAL1-dependent leukemias, particularly T-ALL where TAL1 activation plays a crucial oncogenic role .